Acta Scientific Cancer Biology (ASCB) (ISSN: 2582-4473)

Short Communication Volume 7 Issue 8

The Indigenous Transmutation-Adenocarcinoma in situ Cervix

Anubha Bajaj*

Department of Histopathology, Panjab University/A.B. Diagnostics, India

*Corresponding Author: Anubha Bajaj, Department of Histopathology, Panjab University/A.B. Diagnostics, India./p>

Received: August 24, 2023; Published: September 05, 2023

Abstract

Adenocarcinoma in situ is designated as a cervical intraepithelial lesion constituted of glandular epithelium with a malignant countenance. Adenocarcinoma in situ manifests as a neoplastic glandular precursor of invasive endocervical adenocarcinoma. Untreated lesions display significant possible metamorphosis into invasive adenocarcinoma of uterine cervix. Employment of human papilloma virus (HPV) vaccine is associated with decimated disease incidence, especially in young females.

References

  1. Giannella L., et al. “In situ/Microinvasive Adenocarcinoma of the Uterine Cervix and HPV-Type Impact: Pathologic Features, Treatment Options, and Follow-Up Outcomes-Cervical Adenocarcinoma Study Group (CAS-Group)”. Cancers (Basel)11 (2023): 2876.
  2. Kim W., et al. “Changes in cervical dysplasia, carcinoma in situ, and cervical cancer after expanding the National Cancer Screening Program to younger women in Korea”. International Journal for Quality in Health Care 2 (2023).
  3. Mao P., et al. “Copious vaginal discharge finally diagnosed as cervical adenocarcinoma: A case report”. Medicine (Baltimore)16 (2023): e33614.
  4. Liu J., et al. “Comparison of the safety between cervical conization and hysterectomy for patients with cervical adenocarcinoma in situ”. Journal of Gynecologic Oncology 1 (2023): e8.
  5. Belkić K., et al. “Predictors of treatment failure for adenocarcinoma in situ of the uterine cervix: Up to 14 years of recorded follow-up”. Oncology Letter4 (2022): 357.
  6. Image 1 Courtesy: Pathology outlines.
  7. Image 2 Courtesy: Wikimedia commons.

Citation

Citation: Anubha Bajaj. “The Indigenous Transmutation-Adenocarcinoma in situ Cervix" Acta Scientific Cancer Biology 7.8 (2023): 04-07.

Copyright

Copyright: © 2023 Anubha Bajaj. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days
Impact Factor1.183

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US